|Synta Pharmaceuticals||STA-9090||Oncology||" heat shock protein 90 (Hsp90) inhibitor unrelated to geldanamycin or its family of related compounds, such as 17-AAG"|
|Lexicon Pharmaceuticals||LX2931||Rheumatoid arthritis and other autoimmune disorders||"Inhibits key enzyme in sphingolipid pathway, which controls lymphocyte circulation and trafficking to peripheral sites in the body during an inflammatory response. N.B. IND submitted to US FDA"|
|Trubion Pharamceuticals||TRU-016||Oncology - B-cell malignancies: non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (CLL)||"Depletes B cells by binding to a cell surface protein found in high-levels exclusively on B cells and to a lesser extent on a subpopulation of T cells and myeloid cells. The precise function of the target is not known, though experiments suggest that it plays an important role in B-cell regulation.N.B. IND submitted to US FDA"|
|Lundbeck||Lu AA47070||Parkinson's disease and other neurological disorders||adenosine receptor inhibitor|
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.